Artelo biosciences announces selection of worldwide clinical trials as clinical research organization to support first-in-human study of art26.12

Solana beach, calif., jan. 08, 2024 (globe newswire) -- artelo biosciences, inc.  (nasdaq: artl) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it has selected worldwide clinical trials (“worldwide”), a global award-winning contract research organization (cro) therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease, to support the company's planned phase 1 trial with art26.12, its fatty acid binding protein 5 (fabp5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (cipn).
ARTL Ratings Summary
ARTL Quant Ranking